Large Volume Parenteral (LVP) Market Size
| Study Period | 2019 - 2029 |
| Base Year For Estimation | 2023 |
| CAGR | 4.70 % |
| Fastest Growing Market | Asia Pacific |
| Largest Market | North America |
| Market Concentration | Low |
Major Players
*Disclaimer: Major Players sorted in no particular order |
Need a report that reflects how COVID-19 has impacted this market and its growth?
Large Volume Parenteral (LVP) Market Analysis
The Global Large Volume Parenteral (LVP) Market size is expected to grow from USD 9.96 million in 2023 to USD 12.55 million by 2028, at a CAGR of 4.70% during the forecast period.
COVID-19 significantly impacted the LVP market due to the increased utilisation of dextrose, lactated ringer injection, ringer injection, and sodium chloride injection among COVID-19-infected patients to maintain their fluid balance. This significantly raised the demand for LVP during the pandemic. For instance, according to the January 2022 update by U.S Pharmacist, the National Institutes of Health recommended the use of balanced crystalloid solutions, such as lactated Ringer's solution, Plasma-Lyte, and Normosol-R, for acute resuscitation of adults with shock and COVID-19. Thus, such an increase in the utilisation of LVPs created a considerable demand, thereby augmenting the market growth during the pandemic. However, in the post-pandemic situation, due to the decline in COVID-19 cases, the use of LVP in COVID-19 patients has also reduced. Besides, the market is expected to grow steadily due to the increased adoption of LVPs in hospitals to treat malnutrition and complications associated with electrolyte and fluid loss.
Factors such as the rising number of surgical procedures and increase in chronic diseases that require fluid replacement therapy are expected to drive the market growth over the forecast period as LVP of dextrose, lactate ringer solutions etc., maintain organ perfusion (hemodynamics) and substrate (oxygen, electrolytes, among others) delivery, which thereby beneficial in patient's overall health outcome. Additionally, the increasing patient pool suffering from chronic disease is one of the major drivers in the large volume parenteral market. For instance, according to the data published by the Australian Institute of Health and Welfare in March 2022, almost half (47%, or 11.6 million) of Australians had one or more common chronic health conditions, including diabetes, cancer, mental and behavioural conditions, and chronic kidney disease in 2021. Chronic illness like cancer is often associated with the occurrence of pain, and therapeutic injections are most commonly used to administer to reduce the pain. Also, these patients must need a proper balance of vital nutrients that help maintain their hydration level, energy, and strength. Thus, administering nutrients through LVPs for chronic disease patients is expected to fuel the market growth over the forecast period.
Additionally, fluid replacement is recommended in haemorrhage, extensive burns, excessive sweating (from a prolonged fever), and prolonged diarrhoea (cholera). Also, bodily fluids can be lost because of surgery, injury, dehydration, disease, or other conditions. In addition, traffic accidents are a significant cause of injury worldwide, as mostly the victim have heavy blood loss in the accident and needs immediate medical attention, which comes under the emergency transfusion procedures and will also impact the LVP market. For instance, according to the Road Accident Statistics in India 2021, more than 412 thousand road accidents were reported by the Police Departments of States and Union Territories (UTs) in India during 2021, causing injuries to more than 384 thousand persons. Thus, owing to the high prevalence of injury cases, the demand for fluid replacement due to bleeding will likely rise, contributing to the market growth over the study period. Moreover, the traumatic injuries that occurred due to accidents led to the increased demand for nutritional updates. For instance, according to the article published in October 2022 in Frontiers Journal, mild traumatic brain injury can increase the nutritional needs of the body, and the administration of vitamin D (100,000 International units (IU)) given as injection via intramuscularly significantly found to improve the vitamin D levels.
Therefore, due to the high prevalence of chronic conditions, increase in injury cases and benefits offered by the LVP in nutrition management, the studied market is expected to witness notable growth over the forecast period. However, challenges in formulating large volumes of parenteral such as achieving drug substance and excipient compatibility, are expected to hinder market growth over the forecast period.
Large Volume Parenteral (LVP) Market Trends
Therapeutics Injections Segment is Expected to Hold a Significant Market Share Over the Forecast Period
Therapeutic injections are administered directly into the joint to reduce inflammation and pain. Due to their long-lasting effects, therapeutic injections are commonly recommended for individuals suffering from chronic joint pain who cannot manage their pain with physical therapy. Factors such as an increase in pain-related diseases such as osteoarthritis, rheumatoid arthritis etc., and a rise in the adoption of therapeutic injections for pain due to their quick action and benefits are expected to fuel the segment growth over the forecast period. For instance, according to the November 2021 update by CDC, 24% of all adults, or 58.5 million people, have arthritis in the United States. Thus, people tend to undergo therapeutic injection treatments to alleviate the pain associated with arthritis, which is expected to drive market growth over the forecast period.
An increase in research studies showing the advantages of therapeutic injection in pain relief is expected to drive segment growth over the study period. For instance, corticosteroid injections are one of the most common types of therapeutic injections, which are used along with an anaesthetic numbing agent to relieve joint pain and inflammation. Common corticosteroids used include triamcinolone, methylprednisolone, and dexamethasone. Also, according to a study published in April 2023 in the Clinical Rehabilitation journal, corticosteroid subdeltoid injection, combined with physiotherapy, was found to be beneficial in chronic subacromial bursitis compared to physiotherapy alone. Furthermore, epidural injections alleviate spinal pain and the pain in the legs or arms from an inflamed spinal nerve. Like corticosteroid injections, epidural injections use an anaesthetic combined with a corticosteroid. For instance, according to a study published in August 2022 in PubMed, epidural steroid injections (ESI) received by the geriatric population for back and leg pain were found to have a long-term improvement with low pain episodes. Thus, owing to the increased benefits of therapeutic injections, the studied segment is expected to witness significant growth over the forecast period.
Hence, the studied segment is expected to witness significant growth over the forecast period due to the increase in the incidence of pain and the rise in the utilisation of therapeutic injections in chronic pain conditions.
North America Anticipated to Hold a Significant Market Share Over the Forecast Period
North America is expected to hold a significant market share over the forecast period owing to robust healthcare infrastructure and a high prevalence of pain-related diseases, as these can increase the utilisation of LVPs. Also, the rise in cases of surgeries coupled with an increase in fluid replacement therapies across North America is further likely to bolster the market growth over the forecast period. For instance, as per the June 2022 update by Canadian Institute for Health Information, approximately 110,000 joint replacements were performed in 2020-2021, of which more than 7,300 were performed as day surgery, representing a four-fold increase from the previous year in Canada. Proper fluid intake is essential for joint replacement surgeries, which is expected to increase the demand for LVP, contributing to market growth in the North American region.
Furthermore, as LVP can continuously disperse a selected drug, generally morphine, through the catheter into the intraspinal space, it is beneficial in pain management among cancer patients. For instance, according to the statistics published by the American Cancer Society, around 1.9 million new cancer cases are expected to be diagnosed in the United States in 2023. Hence, a high prevalence of cancer cases is expected to utilise the LVP in pain management, and the demand for LVPs is likely to rise in the North American region, leading to market growth over the forecast period.
Furthermore, the LVP is commonly used for intravenous fluid resuscitation, as LVP can quickly restore the fluid balance of patients with haemorrhage/burns. For instance, according to an article published in June 2022 by a researcher at Virginia Commonwealth University School of Medicine, isotonic crystalloid solutions are typically given for intravascular repletion during shock and hypovolemia, and colloid solutions (e.g., hydroxyethyl starch, albumin, dextrans) are also effective for volume replacement during significant haemorrhage. Also, traumatic brain injury (TBI) can cause severe hemorrhagic cerebral contusion, leading to the adoption of LVP for fluid replacement purposes. For instance, according to the Traumatic Brain Injury Report 2022 published by the Tennessee Department of Health, 7,838 TBI patients were reported to the registry in 2021 in Tennesee. Thus, the high prevalence of TBI can create a significant demand for the LVP, which is expected to drive market growth over the forecast period.
Thus, owing to the rise in surgical procedures, the adoption of LVPs in the pain management of cancer patients and the increase in healthcare expenditure, North America is expected to hold a significant market share of the studied market over the forecast period.
Large Volume Parenteral (LVP) Industry Overview
The large volume parenteral market is competitive and consists of global and local players. The key players are engaged in various strategic activities such as product launches, mergers and acquisitions to increase their product availability and presence in the studied market. Some of the companies which are currently present in the large volume parenteral (LVP) market are B. Braun SE, Baxter International, Fresenius Kabi AG, Pfizer, Inc., and BML Parenteral Drugs, among others.
Large Volume Parenteral (LVP) Market Leaders
-
BML Parenteral Drugs
-
Pfizer, Inc
-
B. Braun SE
-
Baxter International
-
Fresenius (Fresenius Kabi AG)
*Disclaimer: Major Players sorted in no particular order
Large Volume Parenteral (LVP) Market News
- In November 2022, WuXi STA, a subsidiary of WuXi AppTec, started operating a new parenteral formulation manufacturing line at the drug product site in Wuxi City, China. This new line features a fully automatic vial loading/unloading system and a built-in 15 m2 lyophiliser in a fully enclosed isolator. The filling speed can reach 200 vials per minute, significantly accelerating large-volume parental drug product production speed.
- In June 2022, Akums Drugs & Pharmaceuticals Ltd., a contract manufacturing pharmaceutical company in India, received the stringent European Union (EU) GMP approval for two manufacturing units in Haridwar. One plant manufactures solid oral dosage forms such as tablets, hard gelatin capsules, powders in sachets, etc. belonging to the general category, and another plant manufactures large and small-volume parenteral lines, including vials, ampoules, eyedrops, FFS as well as for dry powder injections in the penicillin line.
Large Volume Parenteral (LVP) Market Report - Table of Contents
1. INTRODUCTION
- 1.1 Study Assumptions and Market definition
- 1.2 Scope of the Study
2. RESEARCH METHODOLOGY
3. EXECUTIVE SUMMARY
4. MARKET DYNAMICS
- 4.1 Market Overview
-
4.2 Market Drivers
- 4.2.1 Rising Number of Surgeries
- 4.2.2 Increase in Prevalence of Chronic Diseases and Rise in Adoption of Fluid Replacement Therapies
-
4.3 Market Restraints
- 4.3.1 Challenges in Formulation of LVPs
-
4.4 Porter's Five Forces Analysis
- 4.4.1 Threat of New Entrants
- 4.4.2 Bargaining Power of Buyers/Consumers
- 4.4.3 Bargaining Power of Suppliers
- 4.4.4 Threat of Substitute Products
- 4.4.5 Intensity of Competitive Rivalry
5. MARKET SEGMENTATION (Market Size by Value - USD million)
-
5.1 By Volume
- 5.1.1 100 ml - 250 ml
- 5.1.2 250 ml - 500 ml
- 5.1.3 500 ml - 1000 ml
- 5.1.4 1000 ml - 2000 ml
- 5.1.5 2000 ml and more
-
5.2 By Application
- 5.2.1 Therapeutic Injections
- 5.2.2 Fluid Balance Injections
- 5.2.3 Nutritious Injections
-
5.3 By Type of Packaging
- 5.3.1 Bottles
- 5.3.2 Bags
-
5.4 Geography
- 5.4.1 North America
- 5.4.1.1 United States
- 5.4.1.2 Canada
- 5.4.1.3 Mexico
- 5.4.2 Europe
- 5.4.2.1 Germany
- 5.4.2.2 United Kingdom
- 5.4.2.3 France
- 5.4.2.4 Italy
- 5.4.2.5 Spain
- 5.4.2.6 Rest of Europe
- 5.4.3 Asia-Pacific
- 5.4.3.1 China
- 5.4.3.2 Japan
- 5.4.3.3 India
- 5.4.3.4 Australia
- 5.4.3.5 South Korea
- 5.4.3.6 Rest of Asia-Pacific
- 5.4.4 Middle East and Africa
- 5.4.4.1 GCC
- 5.4.4.2 South Africa
- 5.4.4.3 Rest of Middle East and Africa
- 5.4.5 South America
- 5.4.5.1 Brazil
- 5.4.5.2 Argentina
- 5.4.5.3 Rest of South America
6. COMPETITIVE LANDSCAPE
-
6.1 Company Profiles
- 6.1.1 Albert David Ltd.
- 6.1.2 B. Braun SE
- 6.1.3 Baxter International
- 6.1.4 BML Parenteral Drugs
- 6.1.5 Fresenius (Fresenius Kabi AG)
- 6.1.6 Grifols, S.A.
- 6.1.7 Pfizer, Inc.
- 6.1.8 Taj Pharma
- 6.1.9 Higgs Healthcae
- 6.1.10 Alde Medi Impex Ltd
- 6.1.11 ALTHEA Pharma
- *List Not Exhaustive
7. MARKET OPPORTUNITIES AND FUTURE TRENDS
Large Volume Parenteral (LVP) Industry Segmentation
As per the scope of the report, large-volume parenteral are dosages of more than 100 ml volumes of intravenous solutions commonly prescribed to correct fluid and electrolyte disturbances, nutrition, or to act as a vehicle for administering drugs to the body. Commonly used large-volume parenteral preparations include infusions of amino acid, mannitol, dextrose, lactated ringer injection, ringer's injection, and sodium chloride injection. The Large Volume Parenteral (LVP) Market is Segmented by Volume (100 ml - 250 ml, 250 ml - 500 ml, 500 ml - 1000 ml, 1000 ml - 2000 ml, and 2000 ml and more), Application (Therapeutic Injections, Fluid Balance Injections, and Nutritious Injections), Type of Packaging (Bottles and Bags), and Geography (North America, Europe, Asia-Pacific, Middle East and Africa, and South America). The market report also covers the estimated market sizes and trends for 17 countries across major regions globally. The report offers the value (in USD million) for the above segments.
| By Volume | 100 ml - 250 ml | |
| 250 ml - 500 ml | ||
| 500 ml - 1000 ml | ||
| 1000 ml - 2000 ml | ||
| 2000 ml and more | ||
| By Application | Therapeutic Injections | |
| Fluid Balance Injections | ||
| Nutritious Injections | ||
| By Type of Packaging | Bottles | |
| Bags | ||
| Geography | North America | United States |
| Canada | ||
| Mexico | ||
| Geography | Europe | Germany |
| United Kingdom | ||
| France | ||
| Italy | ||
| Spain | ||
| Rest of Europe | ||
| Geography | Asia-Pacific | China |
| Japan | ||
| India | ||
| Australia | ||
| South Korea | ||
| Rest of Asia-Pacific | ||
| Geography | Middle East and Africa | GCC |
| South Africa | ||
| Rest of Middle East and Africa | ||
| Geography | South America | Brazil |
| Argentina | ||
| Rest of South America |
Large Volume Parenteral (LVP) Market Research FAQs
What is the current Global Large Volume Parenteral (LVP) Market size?
The Global Large Volume Parenteral (LVP) Market is projected to register a CAGR of 4.70% during the forecast period (2024-2029)
Who are the key players in Global Large Volume Parenteral (LVP) Market?
BML Parenteral Drugs , Pfizer, Inc, B. Braun SE, Baxter International and Fresenius (Fresenius Kabi AG) are the major companies operating in the Global Large Volume Parenteral (LVP) Market.
Which is the fastest growing region in Global Large Volume Parenteral (LVP) Market?
Asia Pacific is estimated to grow at the highest CAGR over the forecast period (2024-2029).
Which region has the biggest share in Global Large Volume Parenteral (LVP) Market?
In 2024, the North America accounts for the largest market share in Global Large Volume Parenteral (LVP) Market.
What years does this Global Large Volume Parenteral (LVP) Market cover?
The report covers the Global Large Volume Parenteral (LVP) Market historical market size for years: 2019, 2020, 2021, 2022 and 2023. The report also forecasts the Global Large Volume Parenteral (LVP) Market size for years: 2024, 2025, 2026, 2027, 2028 and 2029.
Large Volume Parenteral Industry Report
Statistics for the 2024 Large Volume Parenteral market share, size and revenue growth rate, created by Mordor Intelligence™ Industry Reports. Large Volume Parenteral analysis includes a market forecast outlook to 2029 and historical overview. Get a sample of this industry analysis as a free report PDF download.
